TalkMed Group (SGX:5G3) ROCE % : 50.45% (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is TalkMed Group ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. TalkMed Group's annualized ROCE % for the quarter that ended in Dec. 2023 was 50.45%.

TalkMed Group ROCE % Historical Data

The historical data trend for TalkMed Group's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TalkMed Group ROCE % Chart

TalkMed Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

49.74

28.70

30.46

40.36

42.82

TalkMed Group Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial															32.55	31.49	48.90	38.42	50.45

TalkMed Group ROCE % Calculation

TalkMed Group's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	38.172	/	( ( (109.166 - 19.383)	+	(115.786 - 27.278) )	/ 2 )
	=	38.172	/	( (89.783	+	88.508)	/ 2 )
	=	38.172	/	89.1455
	=	42.82 %

TalkMed Group's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	43.204	/	( ( (105.776 - 23.023)	+	(115.786 - 27.278) )	/ 2 )
	=	43.204	/	( ( 82.753	+	88.508 )	/ 2 )
	=	43.204	/	85.6305
	=	50.45 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

TalkMed Group (SGX:5G3) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

TalkMed Group ROCE % Related Terms

Thank you for viewing the detailed overview of TalkMed Group's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

TalkMed Group (SGX:5G3) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » TalkMed Group Ltd (SGX:5G3) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

3 Mount Elizabeth, Mount Elizabeth Hospital Level 2, Singapore, SGP, 228510

Website

https://www.talkmed.com.sg

TalkMed Group Ltd operates as an investment holding company. It is a provider of medical oncology, stem cell transplants and palliative care services, serving patients in Singapore and the region. Outside Singapore, the Group operates in Vietnam, Hong Kong and the People's Republic of China. The activities of the company are the provision of medical oncology services and palliative care healthcare services in Singapore. It is organized into three reportable operating segments, Oncology Services, Stem Cells Services and Cellular and gene therapy-related products and services. The company has operational footprints across Singapore, Hong Kong and Vietnam of which Singapore contributes the vast majority of total revenue. It generates maximum revenue from the Oncology services segment.

TalkMed Group (SGX:5G3) Headlines

No Headlines